EDISON, N.J., Sept. 1, 2015 /PRNewswire/ -- The Musculoskeletal Transplant Foundation (MTF) [www.mtf.org] reconfirms today that the Patent Trial and Appeal Board of the United States Patent and Trademark Office has ruled in favor of MTF's inter partes review challenge to the EpiFix® patent (U.S. Patent No. 8,372,437) asserted in the related lawsuit brought by MiMedx Group, Inc. (MiMedx: MDXG) against MTF, Liventa Bioscience, Inc., and Medline Industries, Inc. The '437 Patent is the initial patent in a family that includes two other EpiFix® patents involved in the MiMedx lawsuit (i.e., US Patent Nos. 8,597,687 and 8,709,494).
MTF stands by all statements made in its press release of August 26, 2015.
About MTF - The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987 MTF has received tissue from more than 100,000 donors and distributed more than six million grafts for transplantation. For more information visit: www.mtf.org
For further information
SOURCE Musculoskeletal Transplant Foundation